Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on engineering antibodies into impactful medicines to treat infectious diseases and cancer. Since 2025, Humabs BioMed AG (acquired by Vir Biotechnology in 2017) operates with a unified brand with Vir Biotechnology.

Location
Additional address info
  • Vir Biotechnology, Inc. (correspondence Humabs BioMed AG)
Canton
Facts & figures
  • Type of organization
    Public company
  • Year of foundation
    2017
  • Number of employees in Switzerland
    50-149
Key business

You may also be interested in